The overall investment opportunities of pharmaceuticals in the future are still optimistic about the industry

【Pharmaceutical Network Market Analysis】As of the close of November 23, the pharmaceutical index fell by more than 3%, including many stocks
such as Huasen Pharmaceutical and Teyi Pharmaceutical.
There is a correction in the pharmaceutical sector, so can there still be investment opportunities? In fact, from the performance of thematic funds, pharmaceutical thematic funds still perform well despite the pullback, and some thematic funds have benefited considerably
.
According to Wind data, the pharmaceutical index has risen by more than 15% since the National Day, and some thematic funds have achieved good excess returns
.
For example, the number of medical theme funds with a cumulative increase of more than 10% since the Chinese Qing exceeded 60, the cumulative increase of Red Earth Innovation Healthcare exceeded 30%, and the Qianhai Open Source Chinese Medicine Research Select A managed by Fan Jie, Changsheng Medical Industry managed by Zhou Sicong, Taikang Medical and Healthcare and other products all rose by about
20%.
Industry analysts believe that since the National Day, affected by factors such as the reduction of the marginal impact of centralized procurement and policy support for traditional Chinese medicine, the pharmaceutical sector has rebounded significantly, and some subdivisions have even risen sharply, so it is also necessary to
pull back.
However, from a fundamental point of view, with the aging of the population, the consumption level continues to upgrade, and the fundamentals of the pharmaceutical sector remain unchanged, so the overall investment opportunity is still worth optimistic
about.
Gülen said in the quarterly report that he is still optimistic about the medium and long-term investment opportunities
in the pharmaceutical and biological sectors.
It will focus on the layout of core innovative drugs, innovative devices, innovative industrial chains, medical services and consumer medical care that it is optimistic about in the long term
.
Looking ahead, it believes that the innovation-related market is far from touching the ceiling of the domestic market, and the overseas market is gradually gaining strength
.
With the improvement of the per capita income and cognitive level of Chinese residents, the demand for medical services and consumer medical care is still growing rapidly and has not been fully satisfied, and the future space is still huge
.
The manager of Golden Eagle Medical and Health Industry Equity Fund also said that the investment opportunities in the pharmaceutical sector in the future are worth looking forward to
.
As the population ages, the demand for medical care is likely to grow
steadily in the future.
From the price point of view, the main core logic that promotes the increase of industrial prices is innovation
.
From the point of view of many securities institutions, it is mainly around the main line of innovation, including innovative drugs, innovative devices and other tracks
.
Among them, in terms of innovative drugs, affected by the crackdown on "pseudo-innovation", although the investment in innovative drugs has fallen in 2021 and the market sentiment has fallen into a downturn, with the strong domestic demand, innovative drug investment is still a general trend
.
"At present, innovative drugs are a cyclical growth stock and are experiencing a certain degree of correction, but as long as the market demand for innovative drug treatment is widespread, the investment in innovative drugs will still maintain a relatively optimistic attitude, and China's innovative drugs are expected to go to the world
in 5-10 years.
" So said the Bosera Healthcare Hybrid Fund Manager
.
In terms of innovative devices, in recent years, the reform of the medical device review and approval system has been further advanced, encouraging medical device innovation and promoting the high-quality development of
the industry.
In view of the innovative and clinically urgently needed medical devices, the Device Review Center has established an innovation and priority review procedure
.
By the end of 2021, 134 innovative medical device products had been approved for marketing, and 44 projects (49 products)
had been approved for marketing in accordance with the priority approval process.
At the same time, with the continuous improvement of the strength of domestic equipment, the product structure is accelerating the upgrading, and the process of domestic substitution is also accelerating
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.